Y-MABS THERAPEUTICS
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer ser... um half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.
Y-MABS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-04-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.ymabs.com
Total Employee:
101+
Status:
Active
Contact:
1 212 847 9841
Email Addresses:
[email protected]
Total Funding:
338.8 M USD
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon LetsEncrypt Mobile Non Scaleable Content HSTS Cloudflare Hosting Pound Sterling Apache 2.4 COVID-19 Digital Ocean
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
ReMission Foundation
An organization dedicated to supporting doctors and scientists researching innovative ways to treat and prevent various forms of cancer.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sofinnova Investments
Sofinnova Investments investment in Private Equity Round - Y-mAbs Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Private Equity Round - Y-mAbs Therapeutics
Scopia Capital
Scopia Capital investment in Private Equity Round - Y-mAbs Therapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Private Equity Round - Y-mAbs Therapeutics
Key Employee Changes
Official Site Inspections
http://www.ymabs.com Semrush global rank: 3.31 M Semrush visits lastest month: 4.24 K
- Host name: 172.67.138.62
- IP address: 172.67.138.62
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Y-mAbs Therapeutics"
Leadership - Y-mAbs Therapeutics, Inc.
Michael Rossi is President, Chief Executive Officer, and a member of the Board of Directors of Y-mAbs Therapeutics. Mr. Rossi has more than 30 years of radiopharmaceutical, drug …See details»
Overview - Y-mAbs Therapeutics, Inc.
My goal is to have these antibodies available worldwide, so that everyone has the same options my daughter and family had. Thomas Gad, Founder of Y-mAbs and father of Daniella, a high …See details»
Y-mAbs Therapeutics, Inc. - LinkedIn
Y-mAbs Therapeutics, Inc. | 7,686 followers on LinkedIn. Innovative pediatric immunotherapies for Real-life Possibilities | Y-mAbs is a commercial-stage clinical biopharmaceutical company …See details»
Y-mAbs Therapeutics - Crunchbase Company Profile & Funding
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform …See details»
Y-mAbs Therapeutics Announces U.S. FDA Clearance of …
Oct 17, 2023 Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform. NEW YORK, Oct. 17, 2023 (GLOBE …See details»
Y-mAbs Names Michael Rossi as President and Chief ... - Markets …
Oct 18, 2023 “After our successful re-organization was implemented and completed back in the first quarter of 2023, I am excited to welcome Michael to the Y-mAbs team and look forward to …See details»
Y-mAbs Appoints Seasoned Biopharma Executive Peter …
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on …See details»
Board of Directors - Y-mAbs Therapeutics, Inc.
Previously, he served as the Chief Financial Officer of INC Research (now known as Syneos Health), a clinical research organization, from February 2011 to August 2013 after having …See details»
Y-mAbs Announces 2020 Financial Results and Recent Corporate ...
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company …See details»
Y-mAbs Medical Info
This medical information website is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced scientific-based answers to …See details»
Y-mAbs Therapeutics, Inc. (YMAB) - Yahoo Finance
Find the latest Y-mAbs Therapeutics, Inc. (YMAB) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Overview - Y-mAbs Therapeutics, Inc.
National Organization for Rare Disorders (NORD): presents a range of comprehensive educational resources for patients, families, and caregivers ... You are about to leave …See details»
Y-mAbs Announces Data to be Presented at the 55th Congress of …
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on …See details»
Y-mAbs Therapeutics, Inc. (YMAB) - Yahoo Finance Canada
Find the latest Y-mAbs Therapeutics, Inc. (YMAB) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Y-mAbs Therapeutics, Inc. (YMAB) - Stock Analysis
6 days ago Website https://www.ymabs.com. Full Company Profile. Financial Performance. In 2023, Y-mAbs Therapeutics's revenue was $84.82 million, an increase of 29.96% compared to …See details»
Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial …
Feb 24, 2022 Y-MABS THERAPEUTICS, INC. Consolidated Statements of Net Loss and Comprehensive Loss (unaudited) (in thousands, except share and per share data) For the …See details»
Corporate Governance - Y-mAbs Therapeutics, Inc.
Y-mAbs — Governance Overview The Board of Directors of Y-mAbs Therapeutics, Inc., sets high standards for the Company’s employees, officers, and directors. Additionally, Y-mAbs has a …See details»
Working at Y-mAbs - Y-mAbs Therapeutics, Inc.
About Y-mAbs Y-mAbs was founded in April 2015 by Thomas Gad, father of a neuroblastoma cancer survivor. Today, Mr. Gad is Chairman of the Board of Directors, and President and …See details»
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial …
Dec 31, 2023 Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash …See details»